El interés en corto de One Group Hospitality da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de One Group Hospitality. Los datos de interés en corto se actualizan cada dos semanas.

One Group Hospitality (NASDAQ:STKS) Bolsa, Informe de interés en corto

One Group Hospitality

The One Group Hospitality

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

The ONE Group Hospitality, Inc. - Common Stock

The One Group Hospitality Inc

On Tuesday, Regeneron Pharmaceuticals&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) &nbsp;reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $8.82</a>.
The <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45061738/regeneron-reports-first-quarter-2025-financial-and-operating-results" rel="noreferrer noopener">company reported sales</a> of $3.03 billion, down 4%, missing the&nbsp;consensus of $3.29 billion.
In the first quarter, U.S. net sales for Eylea HD&nbsp;and Eylea&nbsp;decreased 26% year-over-year to $1.04&nbsp;billion, including $307 million from Eylea HD.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44870253/fda-accepts-priority-review-of-regenerons-flagship-drug-eylea-hd-for-expanded-use" rel="noreferrer noopener">FDA Sets The Countdown: Regeneron&#8217;s Eylea HD Could Be Headed For Major Expansion</a>
Net product sales of Eylea HD increased in the first quarter of 2025, compared to the first quarter of 2024, primarily due to higher sales volumes.
Net product sales of Eylea in the first quarter of 2025, compared to the first quarter of 2024, were negatively impacted by
<ul>
<li>Lower volume due to continued competitive pressures, loss in market share to compounded bevacizumab due to patient affordability constraints, and the continued transition of patients to Eylea HD</li>
<li>Lower net selling price.</li>
</ul>
Regeneron said Eylea&#8217;s net product sales have been, and are likely to continue to be, negatively impacted by increased competition from other anti-VEGF products, including biosimilars, and the transition of patients from Eylea to Eylea HD.
Sanofi collaboration revenue increased in the first quarter of 2025, compared to the first quarter of 2024, due to an increase in the company&#8217;s share of profits from the commercialization of antibodies, which were $1.018 billion and $804&nbsp;million in the first quarter of 2025 and 2024, respectively.
The change in the company&#8217;s share of profits from the commercialization of antibodies was driven by higher profits associated with an increase in Dupixent sales.
Last Tuesday, Regeneron announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supply bulk drug products of Regeneron&#8217;s commercial biologic medicines at their Holly Springs,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" rel="noreferrer noopener">North Carolina, campus</a>.
Guidance: Regeneron now expects a 2025 GAAP gross margin of 83%–84%, down from prior guidance of 84%–85%. The company expects an adjusted gross margin of 86%–87%, compared to the <a target="_blank" href="https://www.benzinga.com/25/02/43470883/regenerons-q4-earnings-surpass-estimates-launches-quarterly-dividend-and-additional-stock-buyback-program" rel="noreferrer noopener">prior guidance of 87%–88%</a>.
On Monday, the European Commission granted conditional marketing approval to Regeneron&#8217;s Lynozyfic (linvoseltamab) to treat adults with relapsed and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45035049/lynozyfic-linvoseltamab-approved-in-the-european-union-for-the-treatment-of-relapsedrefractory-mul" rel="noreferrer noopener">refractory multiple myeloma</a>.
In the&nbsp;U.S., the&nbsp;FDA accepted for review the Biologics License Application for linvoseltamab in adults with R/R MM with a target action date of July 10, 2025.
Price Action: REGN stock is down 6.38% to $571.90 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45073128/pfizers-covid-windfall-shrinks-expands-cost-cutting-efforts" target="_blank" rel="noreferrer noopener">Pfizer&#8217;s Covid Windfall Shrinks, Expands Cost-Cutting Efforts</a></li>
</ul>
Photo by Marianne Campolongo via Shutterstock

Biotech

Earnings

Large Cap

News

Guidance

Health Care

Movers

Trading Ideas

General

REGN

Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides

<a href="https://www.semafor.com/newsletter/04/29/2025/taking-stock-of-donald-trumps-first-100-days-in-offic?utm_source=nowshare&amp;utm_medium=business&amp;utm_campaign=flagshipnumbered6#h" title="https://www.semafor.com/newsletter/04/29/2025/taking-stock-of-donald-trumps-first-100-days-in-offic?utm_source=nowshare&amp;utm_medium=business&amp;utm_campaign=flagshipnumbered6#h">https://www.semafor.com/newsletter/04/29/2025/taking-stock-of-donald-trumps-first-100-days-in-offic?utm_source=nowshare&amp;utm_medium=business&amp;utm_campaign=flagshipnumbered6#h</a>

Brighthouse Financial, Inc. - Common Stock

'Bidders Circle Brighthouse' - Semafor

While crude prices continue to decline,<a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener"> oil-linked ETFs</a> are not only being watched for their price action but also for the insight they provide into sentiment across various segments of the <a href="https://www.benzinga.com/topic/oil" target="_blank" rel="noopener">energy sector</a>. Two of the most heavily followed funds—United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) and SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>)—provide different perspectives on how market players are positioned on oil volatility.
United States Oil Fund
USO is intended to replicate the daily movements of West Texas Intermediate (WTI) crude oil futures. It does this mainly through holding near-month NYMEX futures contracts, and as such, it is extremely vulnerable to short-term changes in the price of oil. The ETF <a href="https://www.uscfinvestments.com/uso">owns </a>a series of front-month WTI futures contracts and rolls them over on a monthly basis. This exposes the fund to contango and backwardation, two states in the futures curve that can either drain or enhance returns independent of spot price direction.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/45018013/oil-drops-below-key-support-is-55-the-next-stop-for-west-texas-intermediate">Oil Drops Below Key Support: Is $55 The Next Stop For West Texas Intermediate?</a>
Through April 29, USO has dropped almost 3% as of writing, echoing weakness in crude. For the past month, its decline, at more than 14%, has intensified as Brent and WTI are on track for a bad month.
USO tends to function as a short-term tactical trading tool instead of a long-term investment tool. Its April movement indicates increasing angst regarding short-term demand destruction with trade disruptions, risk of oversupply, and macroeconomic weakness.
SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF
Whereas USO tracks the commodity, XOP <a href="https://www.ssga.com/us/en/intermediary/etfs/spdr-sp-oil-gas-exploration-production-etf-xop">invests </a>in an equal-weighted index of U.S. energy stocks that are engaged in upstream oil and gas production. The ETF offers diversified exposure to small- and mid-cap exploration and production (E&amp;P) companies. Its equal-weighting approach minimizes concentration risk but maximizes volatility, particularly in times of declining oil prices.
Top Holdings: CNX Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>), Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), and Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) are among the fund&#8217;s top holdings—companies that are more exposed to commodity price fluctuations because of their relatively high-cost production and capital sensitivity.
XOP fell 0.9% Tuesday afternoon, although it has beaten USO on a relative basis over the last few weeks. That is possibly driven by a perception that equities—particularly those with solid balance sheets—can better withstand short-term price dips than the futures curve.
XOP will be ideal for investors looking for leveraged exposure to oil prices through equities when prices are moving higher. Yet, in a bear market like the current one, its small-cap bias makes it a riskier play.
Sentiment Shifts
Brent crude&nbsp;dropped&nbsp;below $63.96 a barrel on Tuesday afternoon, while West Texas Intermediate (WTI)&nbsp;was&nbsp;around $60.34—both&nbsp;<a href="https://oilprice.com/oil-price-charts/">lower&nbsp;</a>for a second&nbsp;straight&nbsp;session. Brent, which has dropped 16% year-to-date, is now set to register its biggest monthly drop&nbsp;since 2021, a reflection of&nbsp;growing&nbsp;worries&nbsp;over&nbsp;weakening&nbsp;demand and geopolitical&nbsp;uncertainty.
At the same time, <a href="https://www.bloomberg.com/news/articles/2025-04-28/latest-oil-market-news-and-analysis-for-april-29">OPEC+&#8217;s</a> hint at bringing production levels back online is exerting downward pressure on prices, with oversupply fears rising as much as the demand outlook weakens, according to Bloomberg.
Geopolitical events are further complicating matters. Negotiations between Tehran and Washington on Iran&#8217;s nuclear program have given tentative indications of progress. If diplomatic efforts result in sanctions easing, Iranian crude might return to global markets—a bearish oil price catalyst once again.
Investors in oil ETFs are also getting hit. As their prices decline, USO and XOP are experiencing increased volume as investors rethink their energy exposure in light of the increased uncertainty.
Looking forward, markets will be waiting to see economic data this week that can provide more clarity on trading conditions. Meanwhile, oil ETFs remain an important gauge of investor sentiment, capturing the fine balancing act of forces at play in the global energy market.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/45075953/exclusive-inside-the-bond-etf-that-thrives-in-volatility-mackay-shields-zachary-aronson-on-ho">EXCLUSIVE: Inside The Bond ETF That Thrives In Volatility—MacKay Shields&#8217; Zachary Aronson On How SECR Is Quietly Crushing It</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Commodities

ETFs

Oil's Slippery Slide: What USO And XOP ETFs Reveal About Energy Market Panic

<a href="https://www.businessinsider.com/tesla-ramps-up-hiring-for-semi-truck-2025-4">https://www.businessinsider.com/tesla-ramps-up-hiring-for-semi-truck-2025-4</a>

TSLA

'Tesla adds over a thousand workers to jumpstart Semi truck production'- Business Insider

Goldman Sachs on Tuesday downgraded Avantor Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) from Buy to Neutral and lowered its <a href="https://www.benzinga.com/quote/AVTR/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $23 to $14</a>.
What Happened: Since being added to the Buy list on June 4, 2021, Avantor shares have plunged 60.1% versus the S&amp;P 500 +30.7 % and the XLV 13.5%, analyst Matthew Sykes explained.
&#8220;We had wrongly assumed that an aggressive cost savings program on the back of a segment reorganization and a bioprocessing business in recovery mode would be enough to continue to drive increased margin expansion and growth,&#8221; Sykes said.
Goldman Sachs&#8217; downgrade reflects broader macro and funding uncertainties.
&#8220;While we remain confident in the company's ability to expand margins, we are concerned that its Laboratory Solutions business will continue to be a drag on overall growth as competitive pressures intensify and macro headwinds persist,&#8221; analyst Sykes adds.
Last Friday, Avantor reported: 
<ul>
<li>Adjusted EPS of <a href="https://www.benzinga.com/general/health-care/25/04/45014623/avantor-sees-steady-earnings-plans-leadership-change-and-strategy-shift" target="_blank" rel="noreferrer noopener">23 cents in line with consensus</a>.</li>
<li>Sales of $1.58 billion, missing the <a href="https://www.benzinga.com/pressreleases/25/04/n45003264/avantor-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">consensus of $1.61 billion</a>.</li>
<li>Sales fell 6% compared to the first quarter of 2024. </li>
<li>Foreign currency translation had a negative impact of 1%, resulting in a sales decline of 2% on an organic basis.</li>
<li>Laboratory Solutions sales were $1.07 billion, a reported decrease of 8%. Sales decreased by 3% organically.</li>
<li>Bioscience Production sales were $516.4 million, a reported decrease of 1%, flat on an organic basis.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/45014623/avantor-sees-steady-earnings-plans-leadership-change-and-strategy-shift" rel="noreferrer noopener">Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift</a>
Why It Matters: Recent economic and policy changes had a notable impact on Avantor this quarter. Customers are cutting back on spending to save money. 
Although there are some encouraging signs of improvement in bioprocessing orders, the analyst is more concerned about Avantor's product mix, which hasn't held up as well as we expected.
Goldman sees valuation as supportive at these levels but less attractive than Buy-rated names in their coverage universe as the market looks for sustainable growth improvement.
On Monday, several analysts downgraded and lowered the price target for Avantor, including:
<ul>
<li>Baird maintained the Outperform rating for Avantor and lowered the price target from $21 to $17.</li>
<li>Morgan Stanley downgraded Avantor from Overweight to Equal-Weight and lowered the price target from $25 to $15.</li>
<li>Barclays maintained Avantor with an Overweight, lowering the price target from $18 to $15.</li>
<li>Stifel downgraded Avantor from Buy to Hold and lowered the price target from $26 to $14.</li>
<li>RBC Capital maintained Avantor with an Outperform, lowering the price target from $24 to $20.</li>
</ul>
Price Action: Avantor stock is up 0.8% at $12.59 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45075714/novartis-q1-earnings-beat-street-view-ceo-confident-to-deliver-upgraded-2025-guidance" target="_blank" rel="noreferrer noopener">Novartis Q1 Earnings Beat Street View, CEO &#8216;Confident&#8217; In Delivering Upgraded Guidance</a></li>
</ul>
Image: Shutterstock

Analyst Color

Downgrades

Analyst Ratings

AVTR

Goldman Sachs Downgrades Avantor As Shares Spiral 60% Since 2021: 'We Wrongly Assumed...'

WIIM

Cantor Equity Partners shares are trading higher on continued strength after entering into a business combination agreement with Twenty One Capital.

HSBC Holdings, Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSBC#NYSE">HSBC</a>) shares traded higher on Tuesday after the company <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">reported&nbsp;first-quarter&nbsp;results</a>.
Revenue decreased 13%&nbsp;year over year (Y/Y) to&nbsp;$17.6 billion due to business divestments, mainly in Canada and Argentina.
Constant currency revenue, excluding notable items, increased 7% Y/Y to $17.7 billion. Banking net interest income (NII) declined to $10.6 billion&nbsp;from&nbsp;$10.9 billion&nbsp;in the quarter.
Customer loans stood at&nbsp;$945 billion, and deposits came in at&nbsp;$1.67 trillion. At the end of the quarter, the CET1&nbsp;ratio was&nbsp;14.7%.
The company's expected credit losses stood at&nbsp;$0.9 billion&nbsp;in&nbsp;the first quarter of 2025.
Adjusted EPS of $1.95, up from <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">$1.70 a year ago quarter</a>.
Buyback: On April 25, HSBC completed a $2 billion share buyback announced alongside its full-year 2024 results.
The bank intends to initiate a share buyback of up to $3 billion, which is expected to start shortly after the annual general meeting on May 2 2025 and to be completed within the period before the 2025 interim results announcement.
Outlook: For FY25, HSBC continues to target banking NII of around&nbsp;$42 billion&nbsp;and mid-teens return on average tangible equity in&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">each of the three years from 2025 to 2027</a>.
The bank aims to target cost factors in savings from the reorganization, expecting&nbsp;$0.3 billion&nbsp;in reductions in 2025 and an annualized&nbsp;<a target="_blank" href="https://www.benzinga.com//node/43825656" rel="noreferrer noopener">$1.5 billion&nbsp;cut by the end of 2026</a>.&nbsp;
HSBC says that achieving this will require&nbsp;$1.8 billion&nbsp;in severance and other upfront costs over 2025-2026.&nbsp;The bank anticipates Expected Credit Loss (ECL) charges between 30-40 basis points in 2025.
HSBC foresees muted lending growth but strong growth in its Wealth business while maintaining a stable Common Equity Tier 1 (CET1) ratio.
Investors can gain exposure to the stock via Precidian ETFs Trust HSBC Holdings plc ADRhedged (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSBH#NYSE">HSBH</a>) and Elevation Series Trust The Opal International Dividend Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IDVZ#BATS">IDVZ</a>).
Price Action: HSBC shares are up 2.29% at $57.63 at the last check Tuesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com//node/45033865" target="_blank" rel="noreferrer noopener">Trump's Tariff Policies Fuel Recession Fears As Millennials Coach Gen Z On Financial Survival</a></li>
</ul>
Photo by TungCheung via Shutterstock

Asia

Equities

HSBC

HSBH

Elevation Series Trust The Opal International Dividend Income ETF

IDVZ

Why Is HSBC Stock Trading Higher On Tuesday?

Wave Life Sciences shares are trading higher after Cantor Fitzgerald initiated coverage with an Overweight rating and $10 price target.

The U.S. Food and Drug Administration on Tuesday approved AbbVie Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Rinvoq (upadacitinib), 15 mg, once daily, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">giant cell arteritis (GCA)</a>.
GCA is an inflammation of blood vessels, called arteries, in and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45063491/rinvoq-upadacitinib-receives-u-s-fda-approval-for-giant-cell-arteritis-gca" rel="noreferrer noopener">around the scalp</a>.
Earlier in April, the European Commission approved Rinvoq for giant cell arteritis <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44678235/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-w" rel="noreferrer noopener">in adult patients</a>.
<ul>
<li>Rinvoq is the first and only oral JAK inhibitor approved in the EU,  Iceland, Liechtenstein and Norway for adult patients with GCA.</li>
</ul>
The approvals are supported by the pivotal Phase 3 SELECT-GCA clinical trial results, which met the primary endpoint of sustained remission.
<ul>
<li>46.4% of patients receiving Rinvoq 15 mg in combination with a 26-week steroid taper regimen achieved sustained remission from week 12 to week 52, compared to 29.0% of patients receiving placebo in combination with a 52-week steroid taper regimen; p=0.002.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44937940/abbvies-pipeline-may-be-a-2026-story-but-analyst-likes-the-setup-now" rel="noreferrer noopener">AbbVie&#8217;s Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now</a>
On Friday,&nbsp;AbbVie reported an adjusted EPS of $2.46, up 6.5% year over year and beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.38</a>.
<ul>
<li>The pharmaceutical giant reported sales of $13.34 billion, up 8.4% on a reported basis (+9.8% on an operational basis), beating the&nbsp;<a href="https://www.benzinga.com/25/04/45011116/abbvie-q1-earnings-come-ahead-of-expectations-ceo-says-well-positioned-for-long-term" target="_blank" rel="noreferrer noopener">consensus of $12.92 billion</a>.</li>
<li>It reported adjusted earnings per share of $2.46, beating the street view of $2.38.</li>
<li>In the first quarter of 2025, Rinvoq sales reached $1.72 billion, an increase of 57.2% (+59.7%).</li>
<li>BMO Capital Markets on Monday wrote that every quarter seems to tell the same story. Analysts think they've accurately factored in Skyrizi and Rinvoq's growth, only for AbbVie to outperform <a href="https://www.benzinga.com/25/04/45050728/abbvies-immunology-portfolio-poised-to-continue-growing-through-humira-erosion-analyst" target="_blank" rel="noreferrer noopener">expectations once again</a>.</li>
</ul>
Last Thursday, AbbVie&nbsp;submitted a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44977545/abbvie-submits-biologics-license-application-to-u-s-fda-for-trenibotulinumtoxine-trenibote-for-the" rel="noreferrer noopener">Biologics License Application</a> to the FDA for trenibotulinumtoxinE (TrenibotE) for moderate to severe glabellar lines (commonly known as frown lines).
<ul>
<li>TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as eight hours after administration (earliest assessment time) and a shorter duration of effect of two to three weeks. </li>
</ul>
ABBV Price Action: AbbVie stock is up 1.31% at $194.95 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45075714/novartis-q1-earnings-beat-street-view-ceo-confident-to-deliver-upgraded-2025-guidance" target="_blank" rel="noreferrer noopener">Novartis Q1 Earnings Beat Street View, CEO &#8216;Confident&#8217; In Delivering Upgraded Guidance</a></li>
</ul>

ABBV

AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type of Arthritis

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is hovering near a major resistance level around $95,000. Analysts expect the upcoming Core PCE inflation report on Wednesday to be a potential catalyst that could push the apex crypto <a href="https://www.benzinga.com/money/bitcoin-price-prediction">to new all-time highs.</a>
What Happened: In a <a href="https://www.youtube.com/watch?v=frtgrhyme6Q&amp;ab_channel=KevCapitalTA">podcast</a> on April 29, technical analyst Kevin highlighted a technical confluence near the $94,410–$95,581 range, where Bitcoin has temporarily paused after a 30% surge from recent lows. 
"We're at the golden pocket, a major volume node, and the point of control," Kevin said, emphasizing the significance of the current level.
A close above the bull market support band, made up of the 20-week simple moving average and 21-week exponential moving average, adds bullish momentum. 
Still, he cautions that short-term consolidation or a pullback remains possible before the next leg higher.
If Bitcoin retraces, Kevin sees $88,000–$90,000 as a strong support zone, aligning with the 0.5 Fibonacci retracement level, key moving averages and a CME gap near $91,600, which "fill 90+% of the time," adding further credibility to a potential revisit.
Inflation Catalyst
Kevin flagged Wednesday's Core PCE release, the Fed's preferred inflation gauge, as a potential inflection point.
Forecasts expect the number to drop from 0.4% to 0.1%. A cooler-than-expected print could heighten expectations for rate cuts, a move historically supportive of Bitcoin and broader crypto assets.
&#8220;If we get a positive core PCE index number and it&#8217;s much lower than expected, the market is going to start sniffing out rate cuts coming by the Fed," Kevin added noting that monetary easing has been a key driver for crypto markets throughout this cycle.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45048427/watch-this-bitcoin-indicator-to-know-if-a-run-to-100000-is-coming">Watch This Bitcoin Indicator To Know If A Run To $100,000 Is Coming</a>
What's Next: Kevin advises traders who went long near recent lows to consider hedging, rather than fully exiting positions. 
"If you want some downside exposure, there's nothing wrong with a small, short here," he said, noting that such a move could offer protection while maintaining upside exposure.
He also points to a decline in USDT dominance, now hitting its bull market support band and 200-day EMA, as a bullish signal for crypto. 
Negative money flow in USDT dominance suggests any uptick could be short-lived, further supporting continued momentum in Bitcoin.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45076518/bitcoin-is-a-commodity-like-gold-says-commerce-secretary-lutnick">Bitcoin Is A Commodity Like Gold, Says Commerce Secretary Lutnick</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Glued To $95,000 But Wednesday Inflation Data Could Spur A Breakout

WOLF

Wolfspeed shares are trading lower, paring back gains from a sharp rally over the past week.

Leggett & Platt shares are trading higher Tuesday. The company on Monday reported better-than-expected Q1 EPS results and raised its FY25 EPS guidance.

Intel&nbsp;Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)&nbsp;told Reuters on Tuesday that several contract manufacturing customers planned to <a target="_blank" href="https://www.benzinga.com/topic/intel" rel="noreferrer noopener">build test chips</a> for its forthcoming advanced manufacturing process as it struggled to win market share from &nbsp;Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
The chipmaker&#8217;s new 14A technology will follow 18A, which is scheduled to go into production in the second half of 2025, Intel <a href="https://www.bloomberg.com/news/articles/2025-04-29/intel-says-customers-preparing-to-test-new-production-technology?sref=TBDibEcD" target="_blank" rel="noopener">told</a> Bloomberg ahead of its Foundry Direct Connect event on Tuesday. At the event, <a href="https://www.benzinga.com/pressreleases/25/04/b45074209/intel-foundry-gathers-customers-and-partners-outlines-priorities" target="_blank" rel="noreferrer noopener">Intel Foundry Direct Connect</a> will share progress on multiple generations of its core process and advanced packaging technologies.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/04/45008023/intel-weighs-taiwan-semiconductor-partnership-to-boost-chip-game" rel="noreferrer noopener">Intel Weighs Taiwan Semiconductor Partnership To Boost Chip Game</a>
It will also announce new ecosystem programs and partnerships and welcome industry leaders to discuss how a systems foundry approach enables collaboration with partners and unlocks innovation for customers. Intel CEO Lip-Bu Tan will open the event by discussing Intel Foundry&#8217;s progress and priorities as the company drives the next phase of its Foundry strategy. 
Intel told Bloomberg that multiple customers intend to build test chips on the new process node.
CEO Tan shared plans to leverage his relationships in the chip industry to win clients for custom chipmaking.
After assuming charge in March 2025, Tan vowed to reshape Intel, including revamping the company&#8217;s foundry operation.
Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)&nbsp;and Nvidia&nbsp;Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) have reportedly run tests for Intel&#8217;s current advanced manufacturing process, 18A.
Intel reiterated it was planning to ramp up the 18A process to high-volume production in 2025, Reuters reported Tuesday. It plans to manufacture chips with 18A initially at its research and development lab near Hillsboro, Oregon. The company&#8217;s factories in Arizona will ramp up production this year.
Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) senior vice president John Koeter emphasized the successful collaboration between Synopsys and Intel Foundry is advancing the semiconductor industry with silicon-to-system design solutions to meet the evolving needs for AI and high-performance computing applications.
Price Actions:&nbsp;At the last check Tuesday, INTC stock was down 0.46% to $20.43.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/04/45050460/whats-pushing-sony-to-consider-a-semiconductor-spinoff" target="_blank" rel="noreferrer noopener">What&#8217;s Pushing Sony To Consider A Semiconductor Spinoff?</a></li>
</ul>
Photo: Shutterstock

Tech

Media

AVGO

INTC

NVDA

SNPS

Intel Ramps Up New Chip Tech To Take On Taiwan Semiconductor's Global Lead

JinkoSolar Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) stock slipped on Tuesday after the company posted <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45063870/jinkosolar-announces-first-quarter-2025-financial-results" rel="noreferrer noopener">mixed first-quarter 2025 results</a>.
The solar module manufacturer&#8217;s revenue decreased 39.9% year-over-year to $1.908 billion, beating the analyst consensus estimate of $1.89 billion. Adjusted loss per ADS of $2.86 missed the analyst consensus loss estimate of $1.38.
Quarterly shipments totaled 19,130 MW—comprising 17,504 MW of solar modules and 1,626 MW of cells and wafers—representing a 12.7% decline compared to last year.
First-quarter 2025 module shipments reached 17.5 GW, the highest in the industry.
The company posted a gross loss of RMB352.9 million ($48.6 million), with the margin falling to -2.5% due to lower solar module prices, compared to 11.9% a year earlier.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44925565/first-solar-stock-jumps-as-u-s-finalizes-tariffs-on-southeast-asian-solar-panels" rel="noreferrer noopener">First Solar Stock Jumps as U.S. Finalizes Tariffs on Southeast Asian Solar Panels</a>
Operating loss rose to RMB2.87 billion ($394.8 million), up from RMB339.6 million a year ago. Operating loss margin widened to –20.7%, compared to –1.5% a year ago.
As of March 31, 2025, the company had RMB27.38B ($3.77B) in cash, RMB12.79B in receivables, RMB13.26B in inventory, and RMB46.54B in debt.
As of March 31, 2025, the company had RMB27.38 billion ($3.77 billion) in cash, RMB12.79 billion in receivables, RMB13.26 billion in inventory, and RMB46.54 billion in debt.
JinkoSolar&#8217;s 2025 order visibility stands at 60–70% overall, surpassing 80% in the Indo-Pacific and MEA regions. Its N-type TOPCon tandem solar cell set a new efficiency record of 34.22%.
Q2 Guidance: JinkoSolar expects module shipments to range between 20.0 GW and 25.0 GW, reflecting current market demand and order visibility.
2025 Outlook: Module shipments are projected between 85.0 GW and 100.0 GW.
Annual production capacity is expected to reach 120.0 GW for mono wafers, 95.0 GW for solar cells, and 130.0 GW for modules by year-end.
&#8220;Prices across the main segments of the solar industrial chain were low in the first quarter. This, combined with disruptions in demand caused by changes in international trade policies, pressured profit margins in each segment of the integrated solar supply chain. Despite this challenging market environment, we fulfilled our delivery commitments to customers and reduced costs through supply chain optimization, adjustments to production and operation plans, and other measures,&#8221; commented Mr.&nbsp;Xiande Li,&nbsp;JinkoSolar&#8217;s&nbsp;Chairman and Chief Executive Officer
&#8220;Due to a year-over-year decline in shipments to the U.S. market and a continued decline in higher-price overseas orders, our module prices and profitability decreased both year-over-year and sequentially.&#8221;
Price Action: JKS stock traded lower by 6.43% at $16.52 at the last check on Tuesday.
Photo by Robert Way via Shutterstock

JinkoSolar Blames Trade Policy Uncertainty For Demand Disruption, Margin Pressure

IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) shares edged higher on Tuesday as the company raised its quarterly dividend and unveiled a new <a href="https://www.benzinga.com/pressreleases/25/04/b45077011/box-and-ibm-partner-to-bring-new-enterprise-level-ai-models-to-support-content-generation-and-prod" target="_blank" rel="noreferrer noopener">AI-focused collaboration with </a><a href="https://www.benzinga.com/pressreleases/25/04/b45077011/box-and-ibm-partner-to-bring-new-enterprise-level-ai-models-to-support-content-generation-and-prod" target="_blank" rel="noreferrer noopener">Box Inc.</a><a href="https://www.benzinga.com/pressreleases/25/04/b45077011/box-and-ibm-partner-to-bring-new-enterprise-level-ai-models-to-support-content-generation-and-prod" target="_blank" rel="noreferrer noopener"> </a>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>).
IBM bumped up its regular quarterly cash dividend to $1.68 per share, scheduled for payment on June 10, 2025, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45069845/ibm-board-approves-increase-in-quarterly-cash-dividend-for-the-30th-consecutive-year" rel="noreferrer noopener">to shareholders on record as of May 9.</a>
This marks the 30th consecutive year the tech giant has raised its dividend, maintaining a streak of uninterrupted payouts since 1916.
IBM also announced a strategic expansion of its partnership with Box to advance enterprise-grade artificial intelligence adoption.
Also Read:<a target="_blank" href="http://benzinga.com/news/large-cap/25/04/45041909/ibm-commits-30-billion-to-rd-in-us-eyes-next-level-advances-in-mainframes-and-quantum-computing" rel="noreferrer noopener"> IBM Commits $30 Billion To R&amp;D In US, Eyes Next-Level Advances In Mainframes And Quantum Computing</a>
The effort centers on integrating Box AI with IBM&#8217;s watsonx platform to boost productivity through intelligent content management across highly regulated sectors.
The integration enables Box customers to deploy Box AI enhanced by IBM&#8217;s watsonx.ai tools, including access to IBM&#8217;s open-source Granite models and Meta&#8217;s Llama models.
This aims to streamline tasks like document automation, data extraction,= and content analysis, helping organizations unlock insights from unstructured enterprise data.
IBM itself has adopted Box AI internally, embedding the tools into its employee workflows.
Meanwhile, Box has implemented IBM&#8217;s watsonx.governance to oversee its AI lifecycle, ensuring compliance and transparency. The company continues to rely on Red Hat OpenShift, also under IBM&#8217;s umbrella, for agile cloud deployment of its AI tools.
The companies emphasized the importance of responsible AI. &#8220;We&#8217;re empowering enterprises to harness AI responsibly and at scale,&#8221; said Aaron Levie, Box&#8217;s CEO.
Rob Thomas, IBM&#8217;s senior vice president of Software, highlighted the partnership&#8217;s goal to embed AI seamlessly into operational workflows to enhance productivity.
The Box AI with IBM watsonx solution is now available to Box Enterprise Advanced customers through Box AI Studio and APIs.
IBM is a certified reseller of Box offerings that include AI functionality, providing clients direct access to IBM&#8217;s enterprise AI model family.
IBM Price Action: IBM shares are trading higher by 1.40% to $239.46 at publication Tuesday.
Read Next:
<ul>
<li><a href="http://benzinga.com/trading-ideas/25/04/45050322/how-youll-know-the-tariff-troubles-are-over" target="_blank" rel="noreferrer noopener">How You&#8217;ll Know When Tariff Troubles Are Finally Over</a></li>
</ul>
Photo: Shutterstock

Dividends

Markets

What's Going On With IBM Stock Today?

PACCAR Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) shares are trading lower on Tuesday after it<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45064199/paccar-achieves-good-financial-performance-and-record-paccar-parts-revenue" rel="noreferrer noopener"> reported first-quarter results.</a>
The company reported quarterly adjusted earnings per share of $1.46, missing the analyst consensus estimate of $1.59.
Quarterly sales of $6.91 billion (down 16% year over year) missed the street view of $7.17 billion.
Harrie Schippers, president and chief financial officer, said, &#8220;PACCAR is making good progress on substantially resolving the EU civil litigation.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45066479/rare-bullish-signal-just-flashed-on-wall-street-will-it-power-sp-500-to-6000" rel="noreferrer noopener">Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&amp;P 500 To 6,000?</a>
PACCAR Parts achieved quarterly pretax income of $426.5 million, compared to $455.8 million earned in the first quarter of 2024.&nbsp;
The company has produced 1.2 million PACCAR MX engines, leading to a downstream powertrain business opportunity in remanufactured engines. &#8220;PACCAR is investing in a 50,000 sq. ft., $35 million PACCAR engine remanufacturing facility in Columbus, Mississippi,&#8221; shared Harry Wolters, PACCAR vice president.
PACCAR said it is increasing its investment in next generation internal combustion, hybrid and battery-electric powertrains, integrated connected vehicle services, expanded manufacturing capabilities, and advanced driver assistance systems.
The company&#8217;s capital expenditures are projected to be in the range of $700-$800 million and research and development expenses are estimated to be in the range $450-$480 million in 2025.&nbsp;&nbsp;
In addition to the capital and R&amp;D investments, the company said it plans to invest a total project amount of $600-$900 million in its battery joint venture, Amplify Cell Technologies.
The company&#8217;s cash and cash equivalents at end of quarter was $5.517 billion.
PACCAR said that the North American truck market is being affected by uncertain economic conditions and the impact of new tariffs.
U.S. and Canada Class 8 truck industry retail sales are estimated to be in a range of 235,000-265,000 trucks in 2025.
Price Action: PCAR shares are trading lower by 3.36% to $88.95 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45029759/cramers-warning-tariff-chaos-could-derail-tech-earnings-frenzy-this-week" target="_blank" rel="noreferrer noopener">Cramer&#8217;s Warning: Tariff Chaos Could Derail Tech Earnings Frenzy This Week</a></li>
</ul>
Image: Shutterstock

PCAR

PACCAR Misses Q1 Earnings, Blames Tariff Turmoil For Hitting North American Truck Market

In November 2017, Lamborghini gifted Pope Francis a one-of-a-kind Huracán. The <a href="https://www.benzinga.com/news/25/02/43759368/silicon-valley-millionaire-asks-dave-ramsey-if-he-should-buy-a-250000-lamborghini-heres-what-car-nut-ramsey-always-asks-himself">sleek white supercar</a>, detailed with gold stripes along the hood and body, was presented to the pope outside his residence at Casa Santa Marta in Vatican City.
Instead of keeping the luxury ride, Pope Francis blessed and autographed it, then decided to auction it off for charity. By May 2018, the Lamborghini sold at Sotheby&#8217;s in London for an impressive $950,000.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
</ul>
<h2 class="wp-block-heading">Helping Rebuild After ISIS Destruction</h2>
According to the <a href="https://www.catholicnewsagency.com/news/246695/how-pope-francis-used-a-donated-lamborghini-to-help-rebuild-iraqi-christian-communities">Catholic News Agency</a>, the proceeds from the auction were split between several charitable causes personally selected by the pope. A significant portion — about $240,000 — went to Aid to the Church in Need, which used the funds to rebuild parts of Iraq&#8217;s Nineveh Plains devastated by ISIS.
Alessandro Monteduro, director of Aid to the Church in Need Italia, said, &#8220;With the two projects described, Aid to the Church in Need wanted to honor the donation of the Holy Father by concretely placing itself alongside the Christians attacked by ISIS.&#8221;
Pope Francis allocated the rest of the proceeds to other humanitarian causes. Donations were made to support victims of human trafficking through the Pope John XXIII Community, and to fund medical and missionary work in Africa through GICAM and Friends of Central Africa.
Trending: Donald Trump Just Announced a $500 Billion AI Infrastructure Deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">Here's How You Can Invest in the Entertainment Market's Next Big Disruptor for Just $998</a>
<h2 class="wp-block-heading">The Internet Reacts: &#8220;There&#8217;s Someone Out There With A Popeborghini&#8221;</h2>
When the story resurfaced online, <a href="https://www.reddit.com/r/interestingasfuck/comments/1k5qfry/pope_francis_in_november_2017_receiving_a_custom/">Reddit</a> users had a field day. &#8220;So there's someone out there with a Popeborghini?&#8221; one comment joked, earning more than 23,000 upvotes.
Another quipped, &#8220;It just doubled in value,&#8221; now that the <a href="https://www.benzinga.com/25/04/44916290/pope-francis-the-peoples-pope-dies-at-88-tributes-pour-in-from-trump-king-charles-tim-cook-joe-biden-jimmy-fallon-and-more">pope has passed away</a>, while others imagined the pope doing donuts in the Vatican parking lot at the time. Some pointed out the symbolism of the sale, saying Pope Francis, &#8220;wants for nothing and it&#8217;s not worth the public scrutiny to accept&#8221; such extravagant gifts.
The humor flowed freely, but many users also expressed genuine admiration for Francis&#8217; decision to turn an ultra-luxury gift into a powerful act of charity.
See Also: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">Not the First Time</h2>
Pope Francis has made a habit of auctioning off high-end gifts for good causes. In 2013, he sold a Harley-Davidson Dyna Super Glide he had received, fetching about $327,000 for charity, far more than the bike's original value.
Other popes have done similar things. Ferrari once gifted the final Enzo ever made to Pope John Paul II, who declined to keep it. The car was auctioned off to aid victims of the 2004 South Asian tsunami.
Pope Francis&#8217; Lamborghini Huracán wasn&#8217;t just a flashy headline — it resulted in real help for communities desperately trying to rebuild their lives.
&#8220;The pope doesn&#8217;t drive,&#8221; one Reddit user joked. But in this case, he drove something far more important: change.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

In 2017, Lamborghini Gave Pope Francis A Custom Supercar Valued At $950,000. Here's What He Did With It

Domino&#8217;s Pizza Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) reported the <a href="https://www.benzinga.com/news/25/04/45039495/dominos-pizza-q1-operating-margin-shrinks-as-lower-income-consumers-feel-the-pinch">first-quarter FY25 earnings </a>on Monday. Several analysts have provided their opinion on the pizza restaurant chain&#8217;s performance.
BofA Securities analyst Sara Senatore reiterated a Buy rating on the shares and raised the price forecast from $520.00 to $549.00.
Despite Domino's weaker-than-expected Q1 domestic same-store sales growth (SSSG), results aligned with internal plans, including share gains in the QSR pizza segment, said the analyst.
She expects performance to accelerate with innovations like stuffed crust and the DoorDash partnership. Supply chain productivity and sales leverage are seen supporting EBIT growth.
FY25 EPS is raised on stronger SSSG, while second-quarter EPS is trimmed due to a higher tax rate.
RBC Capital Markets analyst Logan Reich reiterated an &#8220;Outperform&#8221; rating on the shares and raised the price target from $500 to $550.
Domino&#8217;s first-quarter results were mixed. International same-store sales (SSS) beat expectations, and U.S. market share gains continued despite consumer headwinds, noted the analyst.
Also Read: <a href="https://www.benzinga.com/news/25/04/45074719/levi-strauss-shareholders-stand-by-dei-policy-amid-political-pushback">Levi Strauss Shareholders Stand By DEI Policy Amid Political Pushback</a>
Japan&#8217;s store closures are mostly complete, and FY25 guidance for SSS, unit growth, and 8%+ EBIT growth (FXN) was reiterated. However, broader category weakness persists, especially among low-income consumers, noted the analyst.
Benchmark analyst Todd Brooks reiterated a Buy rating on the shares and raised the price forecast from $520 to $535.
Domino's expects U.S. same-store sales (SSS) to accelerate in 2H25 and into FY26, driven by two key initiatives: the successful launch of stuffed crust pizza and the upcoming DoorDash rollout, expected to add up to 300bps to SSS.
Management maintained FY25 U.S. SSS guidance at 3%, citing strong value positioning, effective promotions like the &#8220;$9.99 Best Deal Ever,&#8221; and ongoing share gains in both delivery and carryout channels, the analyst opined.
BMO Capital analyst Andrew Strelzik reiterated an &#8220;Outperform&#8221; rating on the shares and raised the price target from $515 to $540.
Domino's U.S. same-store sales (SSS) declined 0.5% in the first quarter, missing expectations due to macro headwinds and tough comparisons, though the company still gained market share.
International SSS rose 3.7%, beating consensus with strength in India and Canada. U.S. comps are expected to accelerate through 2025, driven by the launch of Stuffed Crust and the rollout of DoorDash.
Management reiterated its unit growth guidance and expects minimal impact from tariffs on development.
Price Action: DPZ shares traded higher by 0.19% at $491.56 at last check Tuesday.
Read Next: <a href="https://www.benzinga.com/news/25/04/45069925/coca-cola-boasts-q1-eps-beat-as-revenue-jumps-in-europe-middle-east-and-africa">Coca-Cola Boasts Q1 EPS Beat As Revenue Jumps In Europe, Middle East And Africa</a>
Photo: Shutterstock

Domino's Pizza Will Grow With Stuffed Crust & DoorDash Partnership, Say Analysts

Editor&#8217;s Note: An April 23 version of this SolarBank story has been deleted.

Exclusives

SUUN

April 23 SolarBank Story Has Deleted (CORRECTED)

<a href="https://x.com/lisadnews/status/1917278870912254330?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/lisadnews/status/1917278870912254330?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

PBS Correspondent Lisa Desjardins On X Posts "U.S. Trade Rep Greer told GOP senators that countries are coming to the table on tariff talks, but Europe is not engaging as well."

Comments

One Group Hospitality

Interés en corto

One Group Hospitality (NASDAQ:STKS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL